Thrivent Financial for Lutherans Acquires 219,689 Shares of Zoetis Inc. (NYSE:ZTS)

Thrivent Financial for Lutherans grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 32.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 897,077 shares of the company’s stock after buying an additional 219,689 shares during the quarter. Thrivent Financial for Lutherans owned 0.20% of Zoetis worth $155,517,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Capital World Investors grew its stake in Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after purchasing an additional 57,798 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Zoetis by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after purchasing an additional 178,303 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in Zoetis by 2.3% in the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after purchasing an additional 90,330 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

Zoetis stock opened at $192.73 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The stock has a market capitalization of $87.94 billion, a price-to-earnings ratio of 37.13, a PEG ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The business has a fifty day moving average price of $184.70 and a 200-day moving average price of $174.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 EPS. Equities research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZTS. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.